TY - JOUR. T1 - Dynamic cerebral autoregulation and tissue oxygenation in amnestic mild cognitive impairment. AU - Tarumi, Takashi. AU - Dunsky, David I.. AU - Khan, M. Ayaz. AU - Liu, Jie. AU - Hill, Candace. AU - Armstrong, Kyle. AU - Martin-Cook, Kristin. AU - Cullum, C. Munro. AU - Zhang, Rong. PY - 2014. Y1 - 2014. N2 - BACKGROUND: Vascular disease and dysfunction are associated with the higher risk of Alzheimers disease hypothetically due to cerebral hypoperfusion. Brain perfusion is protected by cerebral autoregulation, which, under normal conditions, maintains a constant cerebral blood flow and brain tissue oxygenation.OBJECTIVE: To determine whether dynamic regulation of cerebral blood flow and tissue oxygenation is impaired in patients with amnestic mild cognitive impairment (aMCI).METHODS: Twenty-seven patients with aMCI and 15 control subjects with normal cognitive function underwent the measurements of cerebral hemodynamics, brain MR imaging, and neurocognitive assessment. Dynamic ...
Background/Aims: Short tests to early detection of the cognitive impairment are necessary in primary care setting, particularly in populations with low educational level. The aim of this study was to assess the performance of Memory Alteration Test ([email protected]) to discriminate controls, patients with amnestic Mild Cognitive Impairment (aMCI) and patients with early Alzheimer´s Dementia (AD) in a sample of individuals with low level of education.Methods: Cross-sectional study to assess the performance of the [email protected] (study test), compared to the neuropsychological evaluation (gold standard test) scores in 247 elderly subjects with low education level from Lima-Peru. The cognitive evaluation included three sequential stages: 1) screening (to detect cases with cognitive impairment); 2) nosological diagnosis (to determinate specific disease); and 3) classification (to differentiate disease subtypes). The subjects with negative results for all stages were considered as cognitively normal (controls). The test
Hippocampal atrophy is the key marker in the pathogenesis of Alzheimers disease (AD), which is associated with white matter (WM) disruption. This type of WM disruption could partly explain AD-related pathology. However, relatively little attention has been directed toward WM disruption which may be independent of these fundamental gray matter (GM) changes in amnestic mild cognitive impairment (aMCI) which is associated with high risk of AD. To evaluate the differences of WM integrity between aMCI patients (N = 32) and healthy controls (N = 31), whole-brain voxel-based methods were applied to diffusion tensor imaging. To explore the possible independence of WM changes from GM loss, an index of hippocampal atrophy was used to partial out GM effects. aMCI patients showed WM disruption in frontal lobe, temporal lobe, internal capsule, cingulate gyrus and precuneus. The findings supported the evidence of independent patterns of degeneration in WM tracts which may co-act in the WM pathological ...
TY - JOUR. T1 - Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. AU - Yaffe, Kristine. AU - Blackwell, T.. AU - Whitmer, Rachel. AU - Krueger, K.. AU - Barrett-Connor, E.. PY - 2006/7/1. Y1 - 2006/7/1. N2 - Background: Biological mechanisms linking diabetes and cognition continue to grow, yet the association remains controversial in elders. Whether glycosylated hemoglobin (HbA 1C) level, a marker of glucose control, is predictive of the development of cognitive impairment or dementia is unknown. We determined the association between HbA 1C level and risk of developing cognitive impairment in older women, mostly without diabetes. Methods: We studied 1983 postmenopausal women (mean age, 67.2 years) with osteoporosis who had HbA 1C level measured at baseline. Development of mild cognitive impairment (MCI) or dementia over 4 years was determined as part of a dementia ancillary study. We analyzed risk of MCI or dementia for every 1% of HbA 1C as ...
Method This was a retrospective cross sectional study. We selected 160 consecutive patients diagnosed with Alzheimers dementia and Amnestic Mild Cognitive Impairment who had a comprehensive battery of neuropsychological tests and a behaviour rating scale of interest for this study recorded in the database. Correlation between apathy with and without depression were tested against frontal lobe test including Trail making A, Trial making B, Letter Fluency, Ideational Fluency, Category fluency, Abstract Thinking and Executive functioning subtest of CAMGOG-R.. ...
Damian, Marinella; Hausner, Lucrezia; Jekel, Katrin; Richter, Melany; Froelich, Lutz; Almkvist, Ove; Boada, Merce; Bullock, Roger; De Deyn, Peter Paul; Frisoni, Giovanni B.; Hampel, Harald; Jones, Roy W.; Kehoe, Patrick; Lenoir, Hermine; Minthon, Lennart; Olde Rikkert, Marcel G. M.; Rodriguez, Guido; Scheltens, Philip; Soininen, Hilkka; Spiru, Luiza; Touchon, Jacques; Tsolaki, Magda; Vellas, Bruno; Verhey, Frans R. J.; Winblad, Bengt; Wahlund, Lars-Olof; Wilcock, Gordon; Visser, Pieter Jelle (2013): Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimers Disease in the European Prospective DESCRIPA Study. In: Dementia and Geriatric Cognitive Disorders, No. 1-2: pp. 1-19 ...
TY - JOUR. T1 - Influence of apolipoprotein e ε4 on rates of cognitive and functional decline in mild cognitive impairment. AU - Whitehair, Danielle C.. AU - Sherzai, Abdullah. AU - Emond, Jennifer. AU - Raman, Rema. AU - Aisen, Paul S.. AU - Petersen, Ronald C.. AU - Fleisher, Adam S.. PY - 2010/9/1. Y1 - 2010/9/1. N2 - Background: Apolipoprotein E ε4 (APOE ε4) allele carrier status has been well established as a risk factor for developing Alzheimers disease. However, the specific influence of APOE ε4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE ε4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). Methods: A total of 516 aMCI participants aged 55-90 years who received placebo or vitamin E from the Alzheimers Disease Cooperative Studys MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and ...
TY - JOUR. T1 - Comparing predictors of conversion and decline in mild cognitive impairment. AU - Landau, S. M.. AU - Harvey, D.. AU - Madison, C. M.. AU - Reiman, E. M.. AU - Foster, N. L.. AU - Aisen, P. S.. AU - Petersen, R. C.. AU - Shaw, L. M.. AU - Trojanowski, J. Q.. AU - Jack, C. R.. AU - Weiner, M. W.. AU - Jagust, W. J.. PY - 2010/7/20. Y1 - 2010/7/20. N2 - Objective: A variety of measurements have been individually linked to decline in mild cognitive impairment (MCI), but the identification of optimal markers for predicting disease progression remains unresolved. The goal of this study was to evaluate the prognostic ability of genetic, CSF, neuroimaging, and cognitive measurements obtained in the same participants. Methods: APOE ε4 allele frequency, CSF proteins (Aβ1-42, total tau, hyperphosphorylated tau [p-tau181p]), glucose metabolism (FDG-PET), hippocampal volume, and episodic memory performance were evaluated at baseline in patients with amnestic MCI (n = 85), using data from a ...
LONDON - Mild cognitive impairment (MCI) is recognised as a condition associated with problems with memory, executive function, language and some visuospatial skill; these problems are noticeable to others and also can be identifies in neuropsychological tests, however, they are not severe enough to interfere with everyday activities.. MCI could possibly develop into dementia, maintain its status or even revert to the normal cognitive status. A considerable share of people with MCI later develop Alzheimers disease (AD).. The cutting-edge research report "Epiomic Epidemiology Series: Mild Cognitive Impairment Forecast in 14 Major Markets 2017-2027" prepared by Black Swan Anaysis limited provides a comprehensive analysis of the dynamics and landscape of the worlds MCI market.. This new topical study contains an all-round overview of MCI with relevant data on the disease risk factors, diagnosis and prognosis as well as uncovers updated information on the prevalent population for 14 major ...
TY - JOUR. T1 - Application of attention network test and demographic information to detect mild cognitive impairment via combining feature selection with support vector machine. AU - Lv, Shipin. AU - Wang, Xiukun. AU - Cui, Yifen. AU - Jin, Jue. AU - Sun, Yan. AU - Tang, Yiyuan. AU - Bai, Ying. AU - Wang, Yan. AU - Zhou, Li. PY - 2010/1/1. Y1 - 2010/1/1. N2 - Mild cognitive impairment (MCI) is now thought as the prodromal phase of Alzheimers disease (AD), and the usual method for diagnosing the disease would be a battery of neuropsychological assessment. The present study proposes to integrate a feature selection scheme with support vector machine (SVM) to identify patients with MCI by using attention network test (ANT) and demographic data. Forty-two patients with MCI and forty-five normal individuals underwent ANT recording, and the reaction time and accuracy of ANT and demographics (age, gender, and educational level) were selected as original features. To select features, we first ...
Mild cognitive impairment (MCI) is defined as the symptomatic predementia stage, characterized by cognitive impairment that is not severe enough to influence the usual activities of daily living. MCI is suggested to be a transitional state between healthy aging and clinically probable Alzheimers disease (AD).
Mild Cognitive Impairment (MCI) is often an early manifestation of Alzheimers disease (AD). The ability to identify MCI has led to hope that health prevention models might work in AD as they have in cancer and heart disease. Interventions which help sustain functioning in MCI may delay progression to a clinical AD diagnosis. To date, interventions aimed at maintaining functioning in MCI have been pharmacologic in nature. The efficacy of these medications in MCI is controversial, and those with MCI are also often interested in other activities they can do to manage their memory loss.. When an individual is noted to have memory difficulties or MCI, a recommendation is often given for the patient to begin taking notes/using a calendar to help with memory or do cognitively stimulating activities. However, there is currently little instruction about how/what specific activities one should do and how effective they may be. The overall goal of this pilot project is to refine delivery of the Memory ...
The Alzheimers Disease Neuroimaging Initiative (ADNI) began in October 2004 as a landmark study with a public-private partnership that gathered and analyzed thousands of brain scans, genetic profiles and biomarkers in blood and cerebrospinal fluid (CSF). Although the original goal was to define biomarkers for use in clinical trials to determine the best way to measure treatment effects of Alzheimers disease (AD), the goal has been expanded to using biomarkers to identify AD at a pre-dementia stage. ADNI1 involves scientists at 59 research centers, 54 in the U.S. and five in Canada. Originally 800 participants were enrolled. This group was comprised of 200 participants with AD, 400 with mild cognitive impairment (MCI) and 200 with normal cognition. In ADNI-GO, an estimated 200 participants with early amnestic MCI (EMCI) were enrolled to understand and characterize the mildest symptomatic phase of AD. An additional 650 participants will be enrolled under ADNI2.. Some of the leading-edge ...
OBJECTIVES: Motor deficiency is associated with cognitive frailty in patients with Mild Cognitive Impairments (MCI). In this study we aimed to test the integrity of the muscle synergy involved in an arm-pointing movement in MCI patients, non-impaired functionally. Thus, we were able to test the hypothesis that early motor indicators exist in this population at a preclinical level. METHODS: The electromyographic signals were collected for 11 muscles in 3 groups: Young Adults (YA), Aged Adults (AA), and MCI patients. The AA and MCI groups presented the same functional status. Each subject performed twenty arm-pointing movements from a standing position. RESULTS: The main differences were (1) delayed activation of the right Biceps Femoris and the right Erector Spinae at L3 in MCI patients and AA compared with YA groups ; (2) earlier activation of the left Obliquus internus in MCI compared with AA group and (3) concerning the left Erector spinae at L3, a delay for the AA compared with YA but an earlier
Due to the increasing number of Americans affected by Alzheimers disease (AD), there is continual interest in understanding the pathology of the disease and its progression. A fairly novel diagnosis relating to AD, mild cognitive impairment (MCI), has furthered this understanding and also holds promise for a better diagnosis and treatment of the disease in the future. MCI is a transition state that exists between normal aging and Alzheimers disease. Many studies have proven that some of the known degenerative changes that exist in AD patients are able to be seen in the beginning stages in MCI patients. There are three categories of MCI including amnestic MCI, multiple domain MCI, and single domain non-memory MCI. The amnestic form of MCI has the most information known and the most research being conducted on it. For AD and MCI early diagnosis is crucial because there is not yet a treatment method that is able to reverse the effects of the disease, only to slow the progression. Therefore, the ...
Background: Recent studies demonstrated benefits of cognitive intervention in mild cognitive impairment (MCI), but few studies have determined long-term effects on cognition, conversion rate to Alzheimers disease, and the role of early intervention.. Method: A 6-month multicomponent cognitive group intervention was applied in participants with single- or multiple-domain amnestic MCI (defined according to Petersens criteria). One group (n = 12) received the intervention at the beginning of the study period and was compared with an active control group (n = 12) who received it after an 8-month time lag. Follow-up assessments were conducted at 15 and 28 months (study period was August 2007-December 2009). The primary outcome was change in cognitive function as determined by changes in scores on the Mini-Mental State Examination and the cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog), and the secondary outcomes were change in specific cognitive and noncognitive functions ...
Hippocampus displayed progressively gender-associated damage in Alzheimers disease. However, gender effects have been largely neglected in studies of amnestic type mild cognitive impairment (aMCI)patients who were believed to represent an early stage of this disease. The goal of this study was to use in vivo neuroimaging techniques to determine whether there were any evidences of gender differences in hippocampal atrophy in aMCI. A region of interest-based magnetic resonance imaging approach ...
Objective: To evaluate the accuracy and clinical utility of phosphorylated tau (p-tau) for the diagnosis and prognosis of Alzheimers disease (AD) and mild cognitive impairment (MCI).. Methods: A meta-analysis was performed of 19 robust studies that compared AD with healthy individuals (n = 2300), 18 that compared AD with non-AD dementias (n = 1892), eight that compared MCI with healthy subjects (n = 447) and six in those with MCI who did and did not progress to dementia (n = 388).. Results: On the basis of levels of p-tau in CSF, AD could be discriminated from those without cognitive impairment with a sensitivity (Se) of 77.6%, a specificity (Sp) of 87.9%, a positive predictive value (PPV) of 90.3% and a negative predictive value (NPV) of 73.0%. The clinical utility of the test was rated as "good". CSF levels of p-tau separated AD from other dementias with an Se of 71.6% and an Sp 77.8% but here the clinical utility was satisfactory to poor. Regarding MCI, p-tau contributed to the separation of ...
The featured paper is Mild Cognitive Impairment: Cognitive Screening or Neuropsychological Assessment? by Diniz and colleagues and freely available here. The authors begin by focusing in the introduction on the definition of Mild Cognitive Impairment (MCI) and the 10% progression to dementia. The expansion of the term MCI to include non-amnestic types together with the…
According to the study of "From mild cognitive impairment to Alzheimers disease - influence of homocysteine, vitamin B12 and folate on cognition over time: results from one-year follow-up" by Siuda J, Gorzkowska A, Patalong-Ogiewa M, Krzystanek E, Czech E, Wiechuła B, Garczorz W, Danch A, Jasińska-Myga B, Opala G., posted in US National Library of Medicine National Institutes of Health, researchers found that Vascular risk factors were found significantly more often in the MCI group (p = 0.041), including APOE4 allele (p = 0.018), hyperhomocysteinaemia (p = 0.012) and folate deficiency (p = 0.023). Discriminant function analysis showed that only age and hypertension are potential factors which may have an influence on progression to dementia in the MCI group within one year of prospective observation ...
|b||i|Background:|/i||/b| Hemodynamic control was compared in patients with mild cognitive impairment (MCI) or mild Alzheimers dementia (AD) as well as in healthy elderly subj
There has been increasing interest in the influence of diet on cognition in the elderly. This study examined the cross-sectional association between dietary patterns and cognition in a sample of 249 people aged 65-90 years with mild cognitive impairment (MCI). Two dietary patterns; whole and processed food; were identified using factor analysis from a 107-item; self-completed Food Frequency Questionnaire. Logistic regression analyses showed that participants in the highest tertile of the processed food pattern score were more likely to have poorer cognitive functioning; in the lowest tertile of executive function (OR 2.55; 95% CI: 1.08-6.03); as assessed by the Cambridge Cognitive Examination. In a group of older people with MCI; a diet high in processed foods was associated with some level of cognitive impairment.
In the last 30 years there has been a long way in what concerns the ability to test and diagnose cognitive disorders. On the other hand, it is more and more obvious the necessity to discover new parameters, which can clearly witness the passage from the physiological state of aging to a cognitive impairment in various stages (ranging from mild cognitive impairment to severe dementia). Bringing together all the clinical, paraclinical and neuropsychological data trying to discover the missing link between metabolic disorders, chronic inflammatory changes, progression of atherosclerosis, and the appearance of cognitive disorders, remains an extremely attractive and challenging field of research. By this study, we observed that there is a slight supremacy of the amnestic-MCI in patients with metabolic syndrome, without being able to extract statistically significant data. The interesting data obtained in this study emphasized the connection between the triglycerides/HDL-cholesterol ratio and the presence of
The long-term study completed by researchers at NYU Langone Medical Center tracked 213 adults with and without SCI over an average of seven years, with data collection taking nearly two decades. Further cognitive decline to MCI or dementia was observed in 54 percent of SCI persons, while only in 15 percent of persons free of SCI. "This is the first study to use mild cognitive impairment as well as dementia as an outcome criterion to demonstrate the outcome of SCI as a possible forerunner of eventual Alzheimers disease," said Barry Reisberg, MD, professor of psychiatry, director of the Fisher Alzheimers Disease Program and director, Clinical Core, NYU Alzheimers Disease Center at NYU Langone Medical Center. "The findings indicate that a significant percentage of people with early subjective symptoms may experience further cognitive decline, whereas few persons without these symptoms decline. If decline does occur in those without SCI symptoms, it takes considerably longer than for those with ...
This article gives a comprehensive overview of cytokine and other inflammation associated protein levels in plasma, serum and cerebrospinal fluid (CSF) of patients with Alzheimers disease (AD) and mild cognitive impairment (MCI). We reviewed 118 research articles published between 1989 and 2013 to compare the reported levels of 66 cytokines and other proteins related to regulation and signaling in inflammation in the blood or CSF obtained from MCI and AD patients. Several cytokines are evidently regulated in (neuro-) inflammatory processes associated with neurodegenerative disorders. Others do not display changes in the blood or CSF during disease progression. However, many reports on cytokine levels in MCI or AD are controversial or inconclusive, particularly those which provide data on frequently investigated cytokines like tumor necrosis factor alpha (TNF-α) or interleukin-6 (IL-6). The levels of several cytokines are possible indicators of neuroinflammation in AD. Some of them might increase
Ronald Petersen, M.D., Ph.D. of the Mayo Clinic, Allan Levey, M.D., Ph.D. Emory University School of Medicine, and other Alzheimers Disease Center investigators reported in the June 9, 2005 issue of the New England Journal of Medicine findings from the Memory Impairment Study. Study participants with mild cognitive impairment who took donepezil (Aricept) were at reduced risk of progressing to Alzheimers disease (Alzheimers) during the first year of the study. Although the benefits for the overall group did not persist, there was a much more significant effect for the subgroup of subjects with a genetic predisposition to develop Alzheimers, which lasted for the entire 3-year study period. Vitamin E was also tested in this study and found to have no effect on preventing conversion from MCI to Alzheimers. This study is important since it is the first to report a delay in transition from MCI to Alzheimers, providing hope that future research may find even more effective ways to delay the onset ...
False-negatives" mean persons at greater risk for Alzheimers disease may not get timely care. Patients can be diagnosed with what is known as mild cognitive impairment (MCI). This is a slight yet noticeable decline in his or her cognitive abilities, such as remembering names or items on a list. Most of these changes may not be severe enough to disrupt his or her daily life. However, if a diagnosis of MCI occurs, the patient is then at an increased risk of eventually developing Alzheimers disease or another type of dementia. Currently, the screening tools that exist for MCI result in a false-negative error rate of more than seven percent. This means that seven percent of patients who do have MCI are misclassified unless more extensive testing is conducted. "There are consequences to misdiagnosis," said first author Emily C. Edmonds, PhD, a postdoctoral fellow of neuropyschology in the Department of Psychiatry at UC San Diego School of Medicine. "At the individual level, people incorrectly ...
Moderate physical exercise combined with computer use late in life is associated with a lower risk of mild cognitive impairment (MCI). The research indicated that while both elements related to lowered risk of MCI, there was an additive interaction that created enhanced value according to Yonas Geda, M.D. who presented the research at the annual meeting of the Academy of Neurology.. A random sample of 926 elderly, ages 70 through 90, completed questionnaires on physical exercise, cognitive activities, and caloric intake during the previous year. All were considered non-demented and the diagnosis of MCI, if appropriate, came later. 817 of the original sample were considered normal cognitively and 109 were diagnosed with MCI.. Significant differences were found between the two groups as the normal subjects were younger, better educated, less likely to suffer depression, and had fewer medical problems. When these factors were controlled, the following was found:. ...
ANN ARBOR, Mich., Oct. 6 /PRNewswire-FirstCall/ -- Adeona Completes 100% Enrollment in its Pivotal Alzheimers Disease and Mild Cognitive Impairment...
Title: Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?. VOLUME: 8 ISSUE: 2. Author(s):M. T. Ferretti and A. C. Cuello. Affiliation:Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Room 1325, Montreal, Quebec, Canada, H3G 1Y6.. Keywords:Preclinical Alzheimers disease, Aβ oligomers, inflammation, transgenic mice, NGF, MMP-9. Abstract: The occurrence of a plaque-dependent inflammation in Alzheimers disease has been extensively documented in both human specimens and transgenic models of the disease. Since insoluble plaques are present in AD patients from early preclinical stages of the pathology, the point at which neuroinflammation first occurs in the progression of the AD pathology is still unknown. In this review we discuss the clinical and experimental evidence for the occurrence of inflammation in preclinical, asymptomatic phases of the progression of the AD pathology. In particular, we discuss the ...
A recent alarming rise of neurodegenerative diseases in the developed world is one of the major medical issues affecting older adults. In this review, we provide information about the associations of physical activity (PA) with major age-related neurodegenerative diseases and syndromes, including Alzheimers disease, vascular dementia, and mild cognitive impairment. We also provide evidence of PAs role in reducing the risks of these diseases and helping to improve cognitive outcomes in older adults. Finally, we describe some potential mechanisms by which this protective effect occurs, providing guidelines for future research.
Mild cognitive impairment (MCI), characterized by memory impairment but little or no decline in everyday function, is a transitional stage between normal aging...
Research in Gerontological Nursing | The current study aimed to understand how older adults with mild cognitive impairment (MCI) perceived their condition following diagnosis and to explain the process of coping with concomitant changes in their lives. Using theoretical sampling methods, in-depth interviews were conducted between August 2015 and September 2017 in 20 older adults with MCI; the collected data were analyzed using the
Symptoms of mild cognitive impairment (MCI) warrant a professional evaluation. Why suffering from confusion when traveling can be a symptom of MCI.
This week, research published in Neurology, the medical journal of the American Academy of Neurology, found that a nicotine patch may improve the memory loss common in mild cognitive impairment (MCI)
Progression of Cognitive Deficit in Older People with Mild Cognitive Impairment Treated with Cerebrolysin. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Milan Fiala & Matteo Pellegrini review research that indicates a role for omega-3 fatty acids in slowing the progression of mild cognitive impairment.
Article: Terriere E, Dempsey MF, Herrmann LL, Tierney KM, Lonie JA, OCarroll R, Pimlott S, Wyper DJ, Herholz K & Ebmeier KP (2010) 5-123I-A-85380 binding to the α4β2-nicotinic receptor in mild cognitive impairment. |i|Neurobiology of Aging|/i|, 31 (11), pp. 1885-1893. http://www.sciencedirect.com/science/journal/01974580; https://doi.org/10.1016/j.neurobiolaging.2008.10.008
Alzheimers disease (AD) patients have visuospatial deficits due to parietal dorsal stream dysfunction. Two distinct dorsal flows have been proposed: the inferior parietal (ventro-dorsal (v-d)) and superior parietal (dorso-dorsal (d-d)) streams. We a
Background. Low vitamin D status is associated with poorer cognitive function in older adults, but little is known about the potential impact on cerebrospinal fluid (CSF) biomarkers and brain volumes. The objective of this study was to examine the relations between plasma 25-hydroxyvitamin D (25(OH)D) and cognitive impairment, CSF biomarkers of Alzheimers disease (AD), and structural brain tissue volumes. Methods. A total of 75 patients (29 with subjective cognitive impairment, 28 with mild cognitive impairment, 18 with AD) referred to the Memory Clinic at Karolinska University Hospital, Huddinge, Sweden were recruited. Plasma 25(OH)D, CSF levels of amyloid beta (A beta(1-42)), total-tau, and phosphorylated tau, and brain tissue volumes have been measured. Results. After adjustment for several potential confounders, the odds ratios (95% confidence interval) for cognitive impairment were as follows: 0.969 (0.948-0.990) per increase of 1 nmol/L of 25(OH) D and 4.19 (1.30-13.52) for 24(OH) D ...
There is a need for increased nosological knowledge to enable rational trials in Alzheimers disease (AD) and related disorders. The ongoing Gothenburg mild cognitive impairment (MCI) study is an attempt to conduct longitudinal in-depth phenotyping of patients with different forms and degrees of cognitive impairment using neuropsychological, neuroimaging, and neurochemical tools. Particular attention is paid to the interplay between AD and subcortical vascular disease, the latter representing a disease entity that may cause or contribute to cognitive impairment with an effect size that may be comparable to AD. Of 664 patients enrolled between 1999 and 2013, 195 were diagnosed with subjective cognitive impairment (SCI), 274 with mild cognitive impairment (MCI), and 195 with dementia, at baseline. Of the 195 (29%) patients with dementia at baseline, 81 (42%) had AD, 27 (14%) SVD, 41 (21%) mixed type dementia (=AD+SVD=MixD), and 46 (23%) other etiologies. After 6 years, 292 SCI/MCI patients were ...
Recently, a large meta-analysis of five genome wide association studies (GWAS) identified a novel locus (rs2718058) adjacent to NME8 that played a preventive role in Alzheimers disease (AD). However, this link between the single nucleotide polymorphism (SNP) rs2718058 and the pathology of AD have not been mentioned yet. Therefore, this study assessed the strength of association between the NME8 rs2718058 genotypes and AD-related measures including the cerebrospinal fluid (CSF) amyloid beta, tau, P-tau concentrations, neuroimaging biomarkers and cognitive performance, in a large cohort from Alzheimers Disease Neuroimaging Initiative (ADNI) database. We used information of a total of 719 individuals, including 211 normal cognition (NC), 346 mild cognitive impairment (MCI) and 162 AD. Although we didnt observe a positive relationship between rs2718058 and AD, it was significantly associated with several AD related endophenotypes. Among the normal cognitively normal participants, the minor allele G
IMPORTANCE Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials. OBJECTIVE To investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017. MAIN OUTCOMES AND MEASURES Global cognitive ...
Computational anatomy methods are now widely used in clinical neuroimaging to map the profile of disease effects on the brain and its clinical correlates. In Alzheimers disease (AD), many research groups have modeled localized changes in hippocampal and lateral ventricular surfaces, to provide candidate biomarkers of disease progression for drug trials. We combined the power of parametric surface modeling and tensor-based morphometry to study hippocampal differences associated with AD and mild cognitive impairment (MCI) in 490 subjects (97 AD, 245 MCI, 148 controls) and ventricular differences in 804 subjects scanned as part of the Alzheimers Disease Neuroimaging Initiative (ADNI; 184 AD, 391 MCI, 229 controls). We aimed to show that a new multivariate surface statistic based on multivariate tensor-based morphometry (mTBM) and radial distance provides a more powerful way to detect localized anatomical differences than conventional surface-based analysis. In our experiments, we studied ...
Background Impairment in instrumental actions of daily living (IADL) begins as individuals with amnestic mild cognitive impairment (MCI) transition to Alzheimers disease (AD) dementia. to three years and baseline FDG PET. The subjective, informant-based Functional Activities Questionnaire was used to assess IADL. General linear models and mixed effects models were used, covarying for demographics, cogniton, and behavior. Results The cross-sectional analysis revealed middle frontal and orbitofrontal hypometabolism were significantly associated with greater IADL impairment. Additionally, the interaction of diagnosis with posterior cingulate and with parahippocampal hypometabolism showed a greater decline in IADL performance as metabolism decreased for the AD dementia relative to the MCI group, and the MCI group relative to the CN group. The longitudinal analysis showed that baseline middle frontal and posterior cingulate hypometabolism were significantly associated with greater rate of increase ...
There is no single, specific test to indicate the presence of MCI. A full evaluation is necessary to diagnose MCI and/or rule out other potential causes of the symptoms.. This thorough evaluation, similar to that for Alzheimers disease, includes a physical examination, neurological examinations, laboratory tests, neuropsychological and memory tests, review of medical history and medications, and clinical observations. The experiences of the patient and close friends or family members are also important to the evaluation process.. Just as there is no single definitive test, there is no specific treatment or cure for MCI. Some doctors recommend taking medications currently prescribed for early-stage or moderate Alzheimers disease to try to maintain cognitive abilities with MCI, but research studies have not provided clear-cut evidence on the benefits.. Mental stimulation and physical exercise keep your mind and body functioning well. Health professionals theorize that whats good for the heart ...
The Biomarkers Consortiums Placebo Data Analysis Project in Alzheimers Disease/Mild Cognitive Impairment Clinical Trials combined placebo data from large clinical trials provided by multiple pharmaceutical companies to create datasets of 3,000 to 5,000 subjects for Alzheimers disease (AD) and mild cognitive impairment (MCI) groups. The goal of the project was to develop better measures of disease progression in terms of outcome measures that have both low variability and are sensitive to change, for use in future clinical trials.. ...
Genetic pathway-based hierarchical clustering analysis of older adults with cognitive complaints and amnestic mild cognitive impairment using clinical and neuroimaging phenotypes Academic Article ...
in Neurology (2004), 63(12), 2332-2340. Objectives: To investigate whether the combination of fluoro-2-deoxy-D-glucose (FDG) PET measures with the APOE genotype would improve prediction of the conversion from mild cognitive impairment (MCI) to ... [more ▼]. Objectives: To investigate whether the combination of fluoro-2-deoxy-D-glucose (FDG) PET measures with the APOE genotype would improve prediction of the conversion from mild cognitive impairment (MCI) to Alzheimer disease ( AD). Method: After 1 year, 8 of 37 patients with MCI converted to AD (22%). Differences in baseline regional glucose metabolic rate (rCMRglc) across groups were assessed on a voxel-based basis using a two-factor analysis of variance with outcome (converters [n = 8] vs nonconverters [n = 29]) and APOE genotype (E4 carriers [E4+] [n = 16] vs noncarriers [E4-] [n = 21]) as grouping factors. Results were considered significant at p , 0.05, corrected for multiple comparisons. Results: All converters showed reduced rCMRglc in ...
Synonyms for cognitive impairment disorder in Free Thesaurus. Antonyms for cognitive impairment disorder. 135 synonyms for disorder: illness, disease, complaint, condition, sickness, ailment, affliction, malady, infirmity, indisposition, untidiness, mess, confusion. What are synonyms for cognitive impairment disorder?